psoriasis from other conditions with similar appearances such as lichen simplex chronicus, nummular eczema, seborrheic dermatitis, and tinea corporis.
PLAQUES
Chronic plaque psoriasis typically is symmetric and bilateral (Figure 1 ). Lesions begin as papules and eventually coalesce to form plaques. Plaques are well demarcated and covered by a silvery scale (Figure 2 ). Plaques exhibit the Auspitz sign (bleeding after the removal of scale) and the Koebner phenomenon (lesions induced by trauma). Most patients (84 percent) with psoriasis report itching; the word psoriasis is derived from the Greek word for itching, "psora." 9 
DISTRIBUTION
The extensor surfaces (elbows and knees) commonly are involved (Figure 3 ), as well as the lower back, scalp (Figure 4) , and nails. Nail changes include onycholysis (separation of the nail from its bed; Figure 5 ), pitting ( Figure 6 ), oil spots (yellow or brown spots caused by cellular debris under the nail), and nail dystrophy. Most patients eventually develop nail involvement, although nail findings precede skin findings in about 4 percent of patients. 10, 11 Older patients and those with longer duration of disease, extensive skin lesions, or joint involvement have more nail involvement. 10, 12 Inverse psoriasis, or flexural psoriasis
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Clinical recommendation
Evidence rating References
The diagnosis of psoriasis usually is based on the clinical appearance of the skin lesions.
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Topical steroids and calcipotriene (Dovonex) are the mainstays of topical therapy and, when used together, they may work better than either agent alone. Chronic Plaque Psoriasis (Figure 7 ), affects intertriginous areas such as the gluteal fold, axillae, and glans of the uncircumcised penis. Scale may not appear in these areas.
COMPLICATIONS
Chronic plaque psoriasis does not affect longevity. The condition may, however, be complicated by several comorbidities including malignancy, arthritis, and emotional distress from the cosmetic effects of the disease. Depression, anxiety, sexual dysfunction, poor self-esteem, and suicidal thoughts may coexist with psoriasis, even in patients with less severe disease. 13 Cohort studies 14 have shown that an increased risk of nonmelanoma skin cancers 14 This risk is higher in patients with more severe disease, but it is not clear whether disease severity or treatment accounts for the increased risk. 14 Psoriatic arthritis is an inflammatory, seronegative arthritis with a variable course. The arthritis typically is asymmetric and involves the fingers and toes (Figure 8 ). Estimates of the prevalence of psoriatic arthritis vary widely, but the authors of one study 12 at a referral center found that one third of patients with psoriasis had arthritis and that, in two thirds of those with arthritis, skin lesions preceded arthritis.
Treatment
GENERAL APPROACH
Patients and physicians should understand that psoriasis is a chronic disease without a cure, and that it is important to have realistic expectations of treatment. Treatment should focus on improvement, not disappearance, of lesions. Complete clearing of lesions usually is not possible in patients who use only topical therapy, and overuse of topical therapies results in more side effects.
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NONDRUG THERAPIES
A variety of nondrug therapies for chronic plaque psoriasis have been suggested, including acupuncture, psychotherapy, lifestyle modifications (e.g., smoking cessation), and dietary supplementation (e.g., vitamin D, fish oil). However, there is insufficient evidence regarding the effectiveness of these treatments.
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TOPICAL THERAPIES
Topical therapies used to manage psoriasis include steroids, vitamin D derivatives, retinoids, immunosuppressants, anthralin (Anthra-Derm), coal tar ointment (Zetar), and several other agents (Table 1) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Topical Steroids. Topical steroids have been the mainstays of treatment for many years. Multiple randomized controlled trials 17 28 found better control at six months when patients applied steroids once weekly.
The side effects of topical steroids include skin atrophy, striae, and tachyphylaxis. Only weak (i.e., nonfluorinated) topical steroids should be used on the face and in skinfolds. Side effects increase with longer duration of use, higher potency, and occlusive dressings.
Vitamin D Derivatives. Vitamin D derivatives, available as calcipotriol in the United Kingdom or calcipotriene (Dovonex) in the United States, work by inhibiting keratinocyte proliferation and improving keratinocyte differentiation. Two systematic reviews 17, 18 of RCTs found that calcipotriene is more effective than placebo and is as effective as potent topical steroids. When calcipotriene is used in combination with topical steroids, psoriasis improves more than with either agent alone. 17, 18, 29, 30 The main side effect of calcipotriene is perilesional skin irritation, although it is rarely severe enough to require cessation of treatment. 18 Topical steroids used in conjunction with calcipotriene may lessen skin irritation. 19 The authors of one RCT 20 found tazarotene to be as effective as topical steroids, with a treatment success rate at 12 weeks for knee and elbow lesions of 65 percent with tazarotene 0.1% versus 66 percent with fluocinonide. In a second RCT, 21 tazarotene 0.1% plus a steroid was more effective and better tolerated than tazarotene alone. The overall response to treatment at 12 weeks was 80 percent in the tazarotene/placebo group and 95 percent in the tazarotene/steroid group (P < .05; number needed to treat [NNT] = 7). 21 No studies have directly compared tazarotene with calcipotriene, but the authors of a recent systematic review 22 found a higher percentage of treatment-related adverse effects in patients using tazarotene. Tazarotene causes perilesional irritation and is teratogenic.
Topical Immunosuppressants. The topical immunosuppressants tacrolimus (Prograf) and pimecrolimus (Elidel) are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis but are used by some physicians for this purpose. One small RCT 23 did not find a difference between tacrolimus and placebo. Recently, two industry-sponsored RCTs found that tacrolimus improved intertriginous and facial psoriasis compared with placebo (NNT = 3), 24 and that pimecrolimus improved intertriginous psoriasis compared with placebo (NNT = 3). 25 Side effects of tacrolimus and pimecrolimus are mainly burning and itching, and both medications are expensive. Skin cancer and lymphoma have been reported after using these drugs, but causative associations are uncertain. 26 Anthralin/Coal Tar. Anthralin and coal tar were once popular treatments for psoriasis when used in combination with ultraviolet B (UVB) light therapy. Both have fallen out of favor because of their poorly tolerated side effects, and neither is more effective than calcipotriene. 18 Miscellaneous. Evidence is insufficient to support the use of aloe vera or capsaicin as treatment for psoriasis. 16 Emollients and keratolytics often are used in conjunction with other topical therapies, but there is scant evidence to support their use alone. 16 Good skin hygiene is important for treating most dermatologic conditions, so keeping skin hydrated with emollients and using keratolytics on flaky skin is recommended.
LIGHT THERAPY
Light therapy includes UVB phototherapy and ultraviolet A (UVA) photochemotherapy, usually administered in specialty centers. UVA photochemotherapy is the combination of ingested psoralen (a photosensitizer) followed by exposure to UVA (psoralen plus UVA [PUVA] therapy). RCTs have shown that both are beneficial, but there is an increased rate of nonmelanoma skin cancer following PUVA therapy. 16 It is not clear whether tanning should be recommended as a treatment for psoriasis. Sunbathing helps clear psoriasis plaques in most patients, but it also increases the risk of skin cancers.
SYSTEMIC TREATMENTS
Systemic therapy for psoriasis includes methotrexate; cyclosporine (Sandimmune); oral retinoids; and, recently, the biologics. According to a recent review, 27 there is strong RCT evidence that cyclosporine is effective and that oral retinoids are moderately effective. There was, however, a lack of RCTs to support the use of methotrexate. 27 Methotrexate, cyclosporine, and oral retinoids all have serious side effects including myelosuppression, hepatotoxicity, renal impairment, and teratogenicity.
The biologics alefacept (Amevive), efalizumab (Raptiva), and etanercept (Enbrel) all have FDA approval for the management of psoriasis, and infliximab (Remicade) may gain approval soon. RCTs, including phases II and III studies, support the effectiveness of these drugs compared with placebo, [31] [32] [33] [34] but they have not yet been compared to each other or other therapies. Table 2 31-34 summarizes the side effects, cost, and monitoring required for the biologics.
Approach to the Patient
Evidence-based guidelines 35 Figure 9 .
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For the initial treatment of psoriasis on limited areas of skin, the most effective treatment is a combination of potent topical steroids and calcipotriene. This recommendation, however, is based on limited evidence. 18, 29, 30 An alternative would be to start with a potent topical steroid, calcipotriene, or a topical retinoid alone. Calcipotriene and topical retinoids can be used long-term, but topical steroids must be used intermittently (i.e., for one to four weeks at a time) because of their side effects. 35 If plaques are small and not bothersome, some patients may choose observation. For patients in whom psoriasis is limited to the scalp, the first-line therapy is usually daily antidandruff shampoo. Steroid solutions, foams, or shampoos may be used intermittently for exacerbations. Mild-to moderate-potency topical steroids or topical immunosuppressants should be used for intertriginous plaques.
Patients who do not respond to the above treatments, or who have lesions that occupy more than 20 percent of their body surface area, are candidates for light therapy, traditional systemic therapy, or the immunomodulating agents. Management of psoriasis usually is undertaken by or in conjunction with a dermatologist. Figure 9 . Algorithm for the management of chronic plaque psoriasis, based on recent guidelines, 35 current evidence, and common practice among American dermatologists.
